Technical Analysis for RGEN - Repligen Corporation

Grade Last Price % Change Price Change
F 171.94 0.53% 0.91
RGEN closed up 0.53 percent on Friday, May 17, 2024, on approximately normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. It was able to bounce off of its 200 day moving average, an important long-term support line. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or a pulls back.
5 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Up

Date Alert Name Type % Chg
Stochastic Sell Signal Bearish 0.00%
200 DMA Support Bullish 0.00%
NR7 Range Contraction 0.00%
Earnings Movers Other 0.00%
Multiple of Ten Bullish Other 0.00%
Weak + Overbought Other 0.00%
Weak, Overbought and Reversal Signs Reversal 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Walk Strength 0.53%
Earnings Movers Other 0.53%

   Recent Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Repligen Corporation Description

Repligen Corporation, a life sciences company, engages in the development, production, and commercialization of consumable products used in the process of manufacturing biological drugs. Its bioprocessing products are sold to various life sciences and biopharmaceutical companies worldwide. The company manufactures Protein A, a critical reagent used to separate and purify monoclonal antibody therapeutics. It also supplies various growth factor products used to increase cell culture productivity during the fermentation stage of drug manufacturing. In addition, the company develops and markets its OPUS brand series of pre-packed ‘plug-and-play' chromatography columns, and provides ELISA test kits to ensure final product quality. Further, Repligen has a portfolio of clinical-stage partnering assets, including a pancreatic imaging agent in Phase 3 development and a orphan drug candidate in Phase 1 development. The company was founded in 1981 and is headquartered in Waltham, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Natural Sciences Monoclonal Antibody 3 D Orphan Drug Consumable Products Chromatography Imaging Agent Bioprocessing Cell Culture Bioprocess Drug Manufacturing Growth Factor Products

Is RGEN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 211.13
52 Week Low 110.46
Average Volume 459,532
200-Day Moving Average 170.73
50-Day Moving Average 175.86
20-Day Moving Average 166.94
10-Day Moving Average 168.78
Average True Range 5.81
RSI (14) 52.38
ADX 17.32
+DI 22.97
-DI 24.93
Chandelier Exit (Long, 3 ATRs) 159.51
Chandelier Exit (Short, 3 ATRs) 169.25
Upper Bollinger Bands 175.53
Lower Bollinger Band 158.34
Percent B (%b) 0.79
BandWidth 10.30
MACD Line -0.64
MACD Signal Line -2.28
MACD Histogram 1.6329
Fundamentals Value
Market Cap 9.6 Billion
Num Shares 55.8 Million
EPS 2.03
Price-to-Earnings (P/E) Ratio 84.70
Price-to-Sales 17.09
Price-to-Book 5.76
PEG Ratio 2.59
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 177.34
Resistance 3 (R3) 176.80 174.45 176.44
Resistance 2 (R2) 174.45 173.08 174.73 176.14
Resistance 1 (R1) 173.20 172.23 173.83 173.74 175.84
Pivot Point 170.85 170.85 171.17 171.13 170.85
Support 1 (S1) 169.60 169.48 170.23 170.14 168.04
Support 2 (S2) 167.25 168.63 167.53 167.74
Support 3 (S3) 166.00 167.25 167.44
Support 4 (S4) 166.54